Print Page  Close Window

Investor Relations Home

Corporate Profile

NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system disorders, through proprietary formulations based on existing drugs that are intended to make a significant difference in patients' lives. NeuroDerm currently has four product candidates in development designed to treat moderate to severe Parkinson’s disease. The company designed its product candidates to overcome major deficiencies of current treatments and achieve enhanced clinical efficacy through continuous, controlled administration, primarily subcutaneously or transdermally.

Title
Download Documentation NeuroDerm Investor Day Slides_April 21 2017

Recent News

More >>
DateTitle 
05/23/17NeuroDerm ND0612H Phase II Trial Results to be Presented in Late-Breaking Session at the 21st International Congress of Parkinson’s Disease and Movement Disorders
- ND0612 head-to-head pilot PK results and ND0701 first-in-man PK results to also be presented - - ND0612 clinical data featured in four additional abstracts - REHOVOT, Israel, May 23, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, today announced that complete data from trial 006 will be showcased in a late-breaking poster session at the 21st International Congre... 
Printer Friendly Version
05/11/17NeuroDerm Announces First Quarter 2017 Financial Results
REHOVOT, Israel, May 11, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, today announced financial results for the first quarter ended March 31, 2017. “We are pleased with our continued clinical progress for our lead product candidates, and remain on track to achieve our anticipated milestones for ND0612 and ND0701,” stated Oded Lieberman, PhD, CEO of NeuroDerm. “Ou... 
Printer Friendly Version
04/20/17NeuroDerm to Ring the Nasdaq Stock Market Opening Bell and Participate in the Parkinson’s Unity Walk
REHOVOT, Israel, April 20, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, today announced that the company’s CEO, Oded S. Lieberman, PhD, will ring The Nasdaq Stock Market Opening Bell in New York on Friday, April 21, 2017. A live stream of the ceremony will be available at http://livestream.com/nasdaq/live from approximately 9:15 a.m. ET until 9:30 a.m. ET. Neuro... 
Printer Friendly Version

Upcoming Events | Past Events

More >>
There are currently no events scheduled.